689293-69-4

Basic information

• Product Name: N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester
• Synonyms: N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester;tert-Butyl [2-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamoyl}amino)ethyl]carbamate;tert-butyl [2-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamoyl}amino)ethyl]carbamate (Related Reference);tert-butyl (2-(3-(1-methyl-5-(tritylamino)-1H-pyrazol-4-yl)ureido)ethyl)carbamate;Carbamic acid, N-[2-[[[[1-methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 689293-69-4
• Molecular Formula: C31H36N6O3
• Molecular Weight: 540.65594
• Mol File: 689293-69-4.mol

Chemical Properties

• Boiling Point: 680.391°C at 760 mmHg
• Flash Point: 365.288°C
• Appearance: /
• Density: 1.17
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.29±0.46(Predicted)
• CAS DataBase Reference: N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester(689293-69-4)
• EPA Substance Registry System: N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester(689293-69-4)

Safety Data

• Hazardous Substances Data: 689293-69-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-[2-[[[[1-Methyl-5-[(triphenylmethyl)amino]-1H-pyrazol-4-yl]amino]carbonyl]amino]ethyl]carbamic acid tert-butyl ester is used as a reagent in chemical synthesis for the production of telmisartan, a medication for treating high blood pressure. Its unique chemical structure, including the pyrazole ring and carbamic acid tert-butyl ester group, plays a crucial role in the synthesis process, making it an essential component in the pharmaceutical industry.

InChI:InChI=1/C31H36N6O3/c1-30(2,3)40-29(39)33-21-20-32-28(38)35-26-22-34-37(4)27(26)36-31(23-14-8-5-9-15-23,24-16-10-6-11-17-24)25-18-12-7-13-19-25/h5-19,22,36H,20-21H2,1-4H3,(H,33,39)(H2,32,35,38)

Upstream product

• 689293-67-2 tert-butyl (2-(3-(5-amino-1-methyl-1H-pyrazol-4-yl)ureido)ethyl)carbamate 
• 76-83-5 trityl chloride 
• 689294-26-6 1-methyl-4-phenoxycarbonylamino-5-triphenylmethylaminopyrazole 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 596-43-0 bromo-triphenyl-methane 
• 689294-25-5 5-amino-1-methyl-4-phenoxycarbonylaminopyrazole 

Relevant articles and documents

Preparation method of carbamyl amino pyrazol derived compound

The invention relates to a preparation method of a carbamyl amino pyrazol derived compound, belongs to the technical field of drug intermediates and aims to solve the problem that an existing synthetic route is complicated and is uneasy to operate. The preparation method of the carbamyl amino pyrazol derived compound comprises the steps that in the presence of an acid-binding agent, a compound shown in a formula II and triphenyl halomethane perform condensation reaction in an organic solvent to obtain an intermediate product compound shown in a formula III; then, in the presence of inorganic base, the compound shown in the formula III is subjected to ester hydrolysis reaction, and a compound shown in a formula IV is obtained; the compound and trinitride perform Curtius rearrangement reaction to obtain a compound shown in a formula V; the compound shown in the formula V and BoxEDA perform condensation reaction to obtain the carbamyl amino pyrazol derived compound. The preparation methodhas the advantages that raw materials are easy to obtain, a reaction route operation is simple, and the product yield and purity are high.

PROCESS FOR THE PREPARATION OF CARBAMOYLAMINO PYRAZOLE DERIVATIVES

The present invention relates to a process for the preparation of carbamoylamino pyrazole derivatives using diacetoxyiodobenzene (ΡhΙ(ΟΑc)2) in combination with a non-nucleophilic base.

INTERMEDIATES IN THE SYNTHESIS OF CEPHALOSPORIN COMPOUNDS

Described herein are crystalline forms of a compound of formula (ΙΙΓ), including toluene solvates ofT A TD-CLE, as well as processes for the preparation thereof and use thereof in the preparation of cephalosporin compounds such as ceftolozane. Provided he

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205

We describe herein the synthesis and biological evaluation of a series of novel cephalosporins with potent activity against Pseudomonas aeruginosa. Introduction of various amino groups to the 4-position of a 3-amino-2-methylpyrazole cephalosporin 3-side c

CEPHEM COMPOUNDS

The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.